Table 2. Participant (inpatients and outpatients combined) characteristics and penalized maximum likelihood logistic regression of typed RSV-cases without co-infection*.
| n RSV-A/B (%B) | OR (95% Ci) | p | Adjusted OR (95% Ci) † | Adjusted p-value† | |
|---|---|---|---|---|---|
| Age group | |||||
| 0-3m | 75/109 (59.2) | Ref. | Ref. | ||
| 3-6m | 53/64 (54.7) | 0.83 (0.52–1.32) | 0.437 | 0.86 (0.54–1.39) | 0.548 |
| 6-12m | 55/49 (47.1) | 0.61 (0.38–1.00) | 0.048 | 0.62 (0.38–1.01) | 0.053 |
| 1-2y | 66/94 (58.8) | 0.98 (0.64–1.51) | 0.926 | 1.06 (0.68–1.65) | 0.788 |
| 2-5y | 42/47 (52.8) | 0.77 (0.46–1.28) | 0.314 | 0.87 (0.52–1.46) | 0.591 |
| Sex | |||||
| Male | 170/209 (55.1) | Ref. | Ref. | ||
| Female | 121/154 (56.0) | 1.03 (0.76–1.41) | 0.829 | 1.01 (0.73–1.39) | 0.974 |
| Hospital | |||||
| Ullevål | 153/159 (51.0) | Ref. | Ref. | ||
| AHUS | 62/85 (57.8) | 1.32 (0.89–1.95) | 0.172 | 1.34 (0.90–2.01) | 0.152 |
| Østfold | 76/119 (61.0) | 1.50 (1.05–2.16) | 0.028 | 1.49 (1.03–2.16) | 0.036 |
| Study season | |||||
| 2015/2016 | 80/144 (64.3) | Ref. | Ref. | ||
| 2016/2017 | 165/159 (49.1) | 0.54 (0.38–0.76) | <0.001 | 0.57 (0.38–0.87) | 0.009 |
| 2018/2019 | 46/60 (56.6) | 0.72 (0.45–1.16) | 0.179 | 0.80 (0.49–1.31) | 0.377 |
| Patient type | |||||
| Out-patient | 127/152 (54.5) | Ref. | Ref. | ||
| Inpatient | 160/205 (56.2) | 1.07 (0.78–1.46) | 0.670 | 1.00 (0.72–1.39) | 0.985 |
| Length of stay | |||||
| <24 hours | 162/192 (54.2) | Ref. | Ref. | ||
| > = 24 hours | 125/165 (56.9) | 1.11 (0.81–1.52) | 0.501 | 1.05 (0.76–1.46) | 0.754 |
| Respiratory support ‡ | |||||
| No | 243/305 (55.7) | Ref. | Ref. | ||
| Yes | 42/53 (55.8) | 1.00 (0.65–1.55) | 0.988 | 1.00 (0.63–1.59) | 0.990 |
| Acute upper respiratory tract infection (URTI) | |||||
| No | 238/292 (55.1) | Ref. | Ref. | ||
| Yes | 53/71 (57.3) | 1.09 (0.74–1.61) | 0.669 | 1.06 (0.70–1.59) | 0.794 |
| Lower respiratory tract infection (LRTI) | |||||
| No | 68/90 (57.0) | Ref. | Ref. | ||
| Yes | 223/273 (55.0) | 0.93 (0.65–1.33) | 0.677 | 0.98 (0.67–1.43) | 0.911 |
| Congenital heart disease or pulmonary disease (including BPD) | |||||
| No | 268/344 (56.2) | Ref. | Ref. | ||
| Yes | 23/19 (45.2) | 0.65 (0.35–1.20) | 0.169 | 0.64 (0.34–1.23) | 0.180 |
| Comorbidities § | |||||
| No | 255/340 (57.1) | Ref. | Ref. | ||
| Yes | 36/23 (39.0) | 0.48 (0.28–0.83) | 0.009 | 0.47 (0.27–0.83) | 0.009 |
| Gestational age <37 weeks | |||||
| No | 255/322 (55.8) | Ref. | Ref. | ||
| Yes | 36/41 (53.3) | 0.90 (0.56–1.45) | 0.666 | 0.88 (0.54–1.44) | 0.619 |
* Patients co-infected with one or more of Influenza, Metapneumovirus, Parainfluenza 1, 2, 3, 4 and Adenovirus, or cases with missing information about coinfections are excluded from this table.
†Age groups, month of hospital contact, and the treating hospital were included as independent variables
‡ Invasive ventilation, Continuous Positive Airway Pressure (CPAP), or Bi-level Positive Airway Pressure (BiPAP)
§ Including trisomy 21, neuromuscular, impairment, congenital heart disease, pulmonary disease, BPD, immunodeficiency, and cancer.